Abstract 467P
Background
To investigate the application effect of evidence-based concept of cluster management model in oncology nutrition case management.
Methods
Experimental observation was conducted on 60 cases of oncology patients, and the study period was from August 2021 to August 2022. In the process of nutritional case management of the patients, 30 cases were included in the observation group to carry out the evidence-based concept of the cluster management mode; the other 30 patients belonged to the control group and received routine nursing guidance. Observe and compare the nutritional status and nursing satisfaction of the two groups of patients.
Results
Before nursing care, the nutritional status (S-Amy (blood amylase), U-Amy (urine amylase), Alb (serum albumin), etc.) of the patients in the two groups was assessed, and no significant difference existed between the observation group and the control group (P > 0.05); after the implementation of different nursing care measures, the nutritional status of the patients in the two groups was compared again and found to be significantly different, and that the nutritional status of the patients in the observation group was significantly better ( P＜0.05). The results of patients' satisfaction with nursing interventions showed that the observation group (96.7%) was significantly higher than the control group (70.0%), with a significant difference (P < 0.05).
Conclusions
In the nutritional case management of oncology patients, the implementation of the evidence-based concept of cluster management mode can significantly improve the nutritional status of patients, help patients to strengthen their physical fitness, which is beneficial to the control of patients' conditions, and the patients' satisfaction with nursing care is high, which is worthy of promotion.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract